HALO (STOCKS)
Halozyme Therapeutics, Inc.
$80.000000
-0.220000 (-0.27%)
Prev close: $80.220000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Helen I. Torley
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $9,350.14M
- Employees
- 350
- P/E (TTM)
- 16.86
- P/B (TTM)
- 18.71
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
9
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$1.72 | $1.66 | +0.0591 | +3.56% |
|
Jun 2025 (Q2)
|
$1.54 | $1.29 | +0.2487 | +19.26% |
|
Mar 2025 (Q1)
|
$1.11 | $0.97 | +0.1430 | +14.79% |
|
Dec 2024 (Q4)
|
$1.26 | $1.18 | +0.0785 | +6.64% |
Financial Statements
| Revenues | $1.24B |
| Benefits Costs and Expenses | $496.91M |
| Cost Of Revenue | $192.06M |
| Costs And Expenses | $505.45M |
| Gross Profit | $1.05B |
| Operating Expenses | $313.40M |
| Selling, General, and Administrative Expenses | $172.31M |
| Research and Development | $70.03M |
| Other Operating Expenses | $71.05M |
| Operating Income/Loss | $737.40M |
| Income/Loss From Continuing Operations After Tax | $595.49M |
| Income/Loss From Continuing Operations Before Tax | $745.94M |
| Income Tax Expense/Benefit | $150.45M |
| Net Income/Loss | $595.49M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $595.49M |
| Net Income/Loss Available To Common Stockholders, Basic | $595.49M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $4.88 |
| Diluted Earnings Per Share | $4.74 |
| Basic Average Shares | 120,428,000 |
| Diluted Average Shares | 124,347,000 |
| Assets | $2.22B |
| Current Assets | $1.33B |
| Inventory | $185.80M |
| Prepaid Expenses | $56.03M |
| Other Current Assets | $1.09B |
| Noncurrent Assets | $892.48M |
| Fixed Assets | $40.58M |
| Intangible Assets | $348.54M |
| Other Non-current Assets | $503.36M |
| Liabilities | $1.72B |
| Current Liabilities | $837.23M |
| Accounts Payable | $15.36M |
| Other Current Liabilities | $821.87M |
| Noncurrent Liabilities | $880.09M |
| Long-term Debt | $1.51B |
| Equity | $503.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $503.92M |
| Liabilities And Equity | $2.22B |
| Net Cash Flow From Operating Activities | $611.00M |
| Net Cash Flow From Operating Activities, Continuing | $611.00M |
| Net Cash Flow From Investing Activities | $225.46M |
| Net Cash Flow From Investing Activities, Continuing | $225.46M |
| Net Cash Flow From Financing Activities | -$571.10M |
| Net Cash Flow From Financing Activities, Continuing | -$571.10M |
| Net Cash Flow | $265.35M |
| Net Cash Flow, Continuing | $265.35M |
| Comprehensive Income/Loss | $580.17M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $580.17M |
| Other Comprehensive Income/Loss | $580.17M |